SARS-CoV-2 como agente causador da COVID-19: Epidemiologia, características genéticas, manifestações clínicas, diagnóstico e possíveis tratamentos / SARS-CoV-2 as the causative agent of COVID-19: Epidemiology, genetic characteristics, clinical manifestations, diagnosis and possible treatments

Authors

  • Vitor de Lima Bezerra Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Thomás Bezerra dos Anjos
  • Lilian Emanuelle Santos de Souza
  • Thiago Bezerra dos Anjos
  • Alexia Mercês Vidal
  • Auvani Antunes da Silva Júnior

DOI:

https://doi.org/10.34119/bjhrv3n4-097

Keywords:

COVID-19, SARS-CoV-2, Manifestações clínicas, Diagnóstico.

Abstract

Objetivo: realizar uma revisão integrativa das principais características da SARS-CoV-2 e dos aspectos epidemiológicos, clínicos e diagnósticos da COVID-19, bem como seus possíveis tratamentos. Metodologia: Com base nesse objetivo, a pesquisa foi realizada com os descritores "COVID-19"; "Coronavírus"; "SARS-CoV-2"; "2019-nCoV" e "Novo coronavírus" nos bancos de dados PUBMED, MEDLINE, SPRINGER e Biblioteca Virtual em Saúde (BVS). Foram selecionados artigos em inglês, português e espanhol publicados no período de 2016 a 2020, excluindo relatos de casos, relatos de experiência e editoriais. Resultados e Discussão: 47 artigos foram identificados como elegíveis. Nestes, existe um consenso sobre o alto grau de transmissibilidade, com pequenas divergências no número básico de reprodução (R0). Também houve grande relevância na avaliação clínica dos pacientes para o diagnóstico. No entanto, para confirmação laboratorial, predominou o uso do teste de reação em cadeia da polimerase com transcriptase reversa (RT-PCR). Os sintomas mais recorrentes nos estudos de observação do paciente incluem febre, tosse, mialgia, fadiga e dispnéia. Quanto ao tratamento farmacológico, não foram identificadas evidências concretas, com consenso sobre o uso de drogas sintomáticas. Conclusão: Assim, dado o alto grau de disseminação do vírus e a ausência de vacinas ou terapias eficazes, destaca-se a necessidade urgente de mais estudos na área.

 

References

ADHIKARI, Sasmita Poudel et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious diseases of poverty, v. 9, n. 1, p. 1-12, 2020.

ARAUJO-FILHO, Jose de Arimateia Batista et al. Pneumonia por COVID-19: qual o papel da imagem no diagnóstico?. Jornal Brasileiro de Pneumologia, v. 46, n. 2, 2020.

BENVENUTO, Domenico et al. The 2019?new coronavirus epidemic: evidence for virus evolution. Journal of medical virology, v. 92, n. 4, p. 455-459, 2020.

Brasil. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Departamento de Atenção Hospitalar, Domiciliar e de Urgência. Protocolo de Tratamento do Novo Coronavírus (2019-nCoV). Brasília, 2020.

CAO, Bin et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 2020.

CARLOS, W. Graham et al. Novel Wuhan (2019-nCoV) Coronavirus. American journal of respiratory and critical care medicine, v. 201, n. 4, p. P7, 2020.

CHEN, Jun et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science), v. 49, n. 1, p. 0-0, 2020a.

CHEN, Nanshan et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, v. 395, n. 10223, p. 507-513, 2020b.

CHEN, L. et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, v. 43, p. E005-E005, 2020c.

CHINA. Administração Nacional de Medicamentos (NMPA). Aprovação de emergência da Administração Estatal de Alimentos e Medicamentos de novos produtos para detecção de coronavírus. 2020.

CHUNG, Michael et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology, v. 295, n. 1, p. 202-207, 2020.

CORMAN, Victor M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, v. 25, n. 3, p. 2000045, 2020.

DEL RIO, Carlos; MALANI, Preeti N. 2019 novel coronavirus—important information for clinicians. Jama, v. 323, n. 11, p. 1039-1040, 2020.

Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College London, March 16, 2020.

GAUTRET, Philippe et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, p. 105949, 2020.

GBINIGIE, Kome; FRIE, Kerstin. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP open, 2020.

HUANG, Chaolin et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, v. 395, n. 10223, p. 497-506, 2020.

JIANG, Fang et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of general internal medicine, p. 1-5, 2020b.

JIANG, H. et al. The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies. Zhonghua Jizhen Yixue Zazhi, v. 29, n. 2, p. 182-6, 2020a.

JIN, Ying-Hui et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research, v. 7, n. 1, p. 4, 2020a.

JIN, Yuefei et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, v. 12, n. 4, p. 372, 2020b.

KANNE, Jeffrey P. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. 2020.

LAKE, Mary A. What we know so far: COVID-19 current clinical knowledge and research. Clinical Medicine, v. 20, n. 2, p. 124, 2020.

LAN, Jun et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, v. 581, n. 7807, p. 215-220, 2020.

LANA, Raquel Martins et al. Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cadernos de Saúde Pública, v. 36, p. e00019620, 2020.

LI, Ruiyun et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science, v. 368, n. 6490, p. 489-493, 2020.

LIU, Tao et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. BioRxiv, 2020.

MEHTA, Puja et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), v. 395, n. 10229, p. 1033, 2020.

MURTHY, Srinivas; GOMERSALL, Charles D.; FOWLER, Robert A. Care for critically ill patients with COVID-19. Jama, v. 323, n. 15, p. 1499-1500, 2020.

PARASKEVIS, Dimitrios et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution, v. 79, p. 104212, 2020.

PHELAN, Alexandra L.; KATZ, Rebecca; GOSTIN, Lawrence O. The novel coronavirus originating in Wuhan, China: challenges for global health governance. Jama, v. 323, n. 8, p. 709-710, 2020.

ROME, Benjamin N.; AVORN, Jerry. Drug evaluation during the Covid-19 pandemic. New England Journal of Medicine, 2020.

ROSA, Sandro G. Viveiros; SANTOS, Wilson C. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública, v. 44, p. e40, 2020.

ROTHAN, Hussin A.; BYRAREDDY, Siddappa N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity, p. 102433, 2020.

RUSSELL, Clark D.; MILLAR, Jonathan E.; BAILLIE, J. Kenneth. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, v. 395, n. 10223, p. 473-475, 2020.

SHANG, Jian et al. Structural basis of receptor recognition by SARS-CoV-2. Nature, v. 581, n. 7807, p. 221-224, 2020.

SINGHAL, Tanu. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics, p. 1-6, 2020.

SONG, Fengxiang et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology, v. 295, n. 1, p. 210-217, 2020.

SURVEILLANCES, Vital. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly, v. 2, n. 8, p. 113-122, 2020.

UDUGAMA, Buddhisha et al. Diagnosing COVID-19: the disease and tools for detection. ACS nano, v. 14, n. 4, p. 3822-3835, 2020.

VAN DOREMALEN, Neeltje et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England Journal of Medicine, v. 382, n. 16, p. 1564-1567, 2020.

WANG, Weier; TANG, Jianming; WEI, Fangqiang. Updated understanding of the outbreak of 2019 novel coronavirus (2019?nCoV) in Wuhan, China. Journal of medical virology, v. 92, n. 4, p. 441-447, 2020.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim Guidance. WHO; 13 March 2020c.

World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 59. [S.l.], 19 Mar. 2020a.

World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 72. [S.l.], 1 Abril 2020b.

World Health Organization. Infection prevention and control during health care when novel coronavirus nCoV infection is suspected. Interim guidance. WHO; January 2020d.

YANG, Penghui; WANG, Xiliang. COVID-19: a new challenge for human beings. Cellular & molecular immunology, v. 17, n. 5, p. 555-557, 2020.

ZHA, Lei et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID?19). Medical Journal of Australia, v. 212, n. 9, p. 416-420, 2020.

ZHOU, Fei et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 2020a.

ZHOU, Shuchang et al. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. American Journal of Roentgenology, v. 214, n. 6, p. 1287-1294, 2020b.

ZHU, Na et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020.

ZUMLA, Alimuddin et al. Coronaviruses—drug discovery and therapeutic options. Nature reviews Drug discovery, v. 15, n. 5, p. 327-347, 2016.

Published

2020-07-17

How to Cite

BEZERRA, V. de L.; DOS ANJOS, T. B.; DE SOUZA, L. E. S.; DOS ANJOS, T. B.; VIDAL, A. M.; JÚNIOR, A. A. da S. SARS-CoV-2 como agente causador da COVID-19: Epidemiologia, características genéticas, manifestações clínicas, diagnóstico e possíveis tratamentos / SARS-CoV-2 as the causative agent of COVID-19: Epidemiology, genetic characteristics, clinical manifestations, diagnosis and possible treatments. Brazilian Journal of Health Review, [S. l.], v. 3, n. 4, p. 8452–8467, 2020. DOI: 10.34119/bjhrv3n4-097. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/13364. Acesso em: 29 mar. 2024.

Issue

Section

Original Papers